( 您好!臺灣時間:2021/05/12 00:39
字體大小: 字級放大   字級縮小   預設字形  


研究生(外文):Chia-Chun Kao
論文名稱(外文):Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma of patients with autoimmune thyroid diseases
指導教授(外文):Gregory J. Tsai
外文關鍵詞:autoimmune thyroid diseaseanti-Ro/SS-Aanti-La/SS-BIsotype
  • 被引用被引用:1
  • 點閱點閱:328
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:11
  • 收藏至我的研究室書目清單書目收藏:0
本研究收集57個Grave’s disease,25個Hashimoto’s thyroiditis且無其他自體免疫相關病症患者,和24個正常人共106支血清進行自體免疫性甲狀腺疾病患者血清中自體抗體分佈之研究發現,有高頻率抗Ro及抗La抗體存在的現象,並且以免疫球蛋白G(immunoglobulin-G)的同種型分佈最常見,免疫球蛋白A居次,免疫球蛋白M最少見,提示了日後在自體免疫性甲狀腺疾病檢查中,抗Ro及抗La抗體檢測的重要性、甲狀腺體分泌及抗原分佈的相關性和探討甲狀腺炎與Sjogren’s syndrome疾病間之關聯性與發展的方向。

To study the isotype distribution of anti-Ro (SS-A) and anti-La (SS-B) antibodies in autoimmune thyroid diseases and the possible pathogenesis.
Materials and Methods:
A total of 106 serum samples from 57 patients with Grave’s disease, 25 patients with Hashimoto’s thyroiditis and 24 healthy controls were tested for the distribution of isotype of autoantibodies against the recombinant Ro 52kD, Ro 60kD, and La 48 kD protein by the enzyme-linked immunosorbent assay (ELISA). Immunoglobulin (Ig)G, IgM, and IgA antibodies to recombinant protein were detected by ELISA, too. For ELISA, a positive result was taken to be greater than 2 standard deviations above the mean of the normal group.
High prevalence of positive result of anti-Ro and anti-La antibodies in plasma of patients with autoimmune thyroid diseases. The distribution of isotype of
anti-La 48 Ab: IgG>IgA>IgM,
anti-Ro 52 Ab: IgG=IgA>IgM,
anti-Ro 60 Ab: IgG>IgA>IgM
The prevalence of anti-Ro and anti-La antibodies and difference in distribution of isotype encourage further workup of autoimmune thyroid diseases with other autoimmune diseases.

誌 謝 I
中文摘要 II
目 錄 IV
第一章 研究背景 1
第二章 材料與方法 5
第三章 結 果 8
第四章 討 論 10
參考文獻 18

1.Weetman AP, McGregor AM: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994;15:788-830.
2.Ruf J, Feldt-Rasmussen U, Hegedus L, Ferrand M, Carayon P: 1994 Bispecific thyroglobulin and thyroperoxidase autoantibodies in patients with various thyroid and autoimmune disease. J Clin Endocrinol Metab 1994;79:1404-1409.
3.Mason DK, Harden RM, Alexander WD: The salivary and thyroid glands. A comparative study in man. Br Dental J 1967;122:485-489.
4.Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ: Sjogren’s syndrome. A clinical, pathological and serogical study of sixty-two cases. Medicine (Baltimore) 1965;44:187-231.
5.Karsh J, Pavlidis N, Weintraub BD, Moutsopoulos HM: Thyroid disease in Sjogren’s syndrome. Arthritis Rheum 1980;23:1326-1329.
6.Loviselli A, Mathieu A, Pala R, Mariotti S, Marongiu C, Mazzoleni AP, Maggio P, Martino E: Development of thyroid disease in patients with primary and secondary Sjogren’s syndrome. J Endocrinol Invest 1988;11:653-656.
7.Hansen BU, Ericsson UB, Henricsson V, Larsson A, Manthorpe R, Warvinge G: Autoimmune thyroiditis and primary Sjogren’s syndrome: Clinical and laboratory evidence of the coexistence of the two disease. Clin Exp Rheumatol 1991;9:137-141.
8.Foster H, Fay A, Charles KP, Walker D, Griffiths I: Thyroid disease and other autoimmune phenomena in a family study of primary Sjogren’s syndrome. Br J Rheumatol 1993;32:36-40.
9.Perez-E B, Kraus A, Lopez G, Cifuentes M, Alarcon-Segovia D: Autoimmune thyroid disease in primary Sjogren’s syndrome. Am J Med 1995;99:480-484.
10.Hansen B, Manthorpe R: Antibodies against SS-B/La and SSA/Ro antigens in patients with primary Sjogren’s syndrome. Scand J Rheumatolo 1986;suppl 61:93-97.
11.Clark G, Reichlin M, Tomasi TB Jr: Characteristics of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol 1969;102:117-122.
12.Mattioli M, Reichlin M: Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Arth Rheum 1974;17:421-429.
13.Alspaugh MA, Tan EM: Antibodies to cellular antigens in Sjogren’s syndrome. J Clin Invest 1975;55:1067-1073.
14.Alspaugh MA, Maddison P: Relation of the identity of certain antigen/antibody systems is systemic lupus erythematosus and Sjogren’s syndrome: an interlaboratory collaboration. Arthritis Rheum 1979;22:796-798.
15.Reichlin M, Rader M, Harley JB, et al: Autoimmune responses to Ro(SS-A) particle are directed to the human antigen. Clin Exp Immunol 1989;76:373-377.
16.Provost TT, Levin LS, Watson RM, et al: Detection of anti-Ro (SS-A) antibodies by gel double diffusion and a sandwich ELISA in systemic and subacute cutaneous erythematosus and Sjogren’s syndrome. J Autoimmun 1991;4:87-96.
17.Gottlieb E, Steitz JA: Function of the mammalian La protein: evidence for its action in transcription termination by RNA polymerase III. ENBO J 1989;8:851-861.
18.Okano Y, Steen VD, Medsger TA: Autoantibody reactivity with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993;119:1005.
19.Alexander EL, Arnett FC, Provost TT, Stevens MB: Sjogren’s syndrome: Association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983;98:155-159.
20.Boey ML, Peebles, CL, Tsay G, Tan EM: Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus. Ann Rheum Dis 1988;47:918-923.
21.Gerraty RP, McKelvie PA, Byrne E: Aseptic meningo-encephalitis in primary Sjogren’s syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand 1993;88:309-311.
22.Tan EM: Antinuclear antibodies: diagnostic markers for atuoimmune disease and probes for cell biology. Adv Immunol 1989;44:93.
23.Wasicek CA, Reichlin M: Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies Ro and La. J Clin Invest 1982;69:835.
24.Harley JB, Sestak AL, Willis LG, et al: A model for disease heterogeneity of systemic lupus erythematosus: Relationship between histocompatibility antigens, autoantibodies, and lymphopenia to renal disease. Arthritis Rheum 1989;32:826.
25.Morita S, Izumi M, Nagataki S: Interactions between TSH binding inhibiting and adenylate cyclase stimulating-antibodies in Grave’s disease. Act Endocrinol (Copenh) 1986;112:517-522.
26.Morita S, Arima T, Matsuda M: Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J Clin Endocrinol Metab 1995;80:1203-1206.
27.Witte T, Hartung K, Sachse C, et al: Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. Rheumatol Int 2000;19:107-111.
28.A. K. Halse, M. C. Marthinussen, et al: Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjogren’s syndrome. Scand J Rheumatol 2000;29:13-19.
29.M. Petri, E. W. Karlson, D.S. Cooper, et al: Autoantibody tests in autoimmune thyroid disease: A case-control study. J Rheumatol 1991;18:1529-1531.
30.Motashi O., Yoh H., Shoko K., et al: Increased serum concentration of soluble CD 30 in patients with Grave’s disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1997;82:1757-1760.
31.H. Towbin, T. Stachelin, J. Gorgon: Electrophoretic transfer of proteins for polyacrylamide gels to nitrocellulous sheets: procedure and some applications. Proc Natl Acas Sci 1979;76:4350-4354.
32.E.C. Hagen: Development and standardization of solid-phase assays for the detectin of anti-neutrophil cytoplasmic antibodies (ANCA) for clinical application: report of large clinical evaluation study. Clin Exp Immunol 1995;101supp.1:29.
33.Blange I, Ringertz NR, Pettersson I: Identification of antigenic regions of the human 52kD Ro/SS-A protein recognized by patient sera. J Autoimmun 1994;7:263-274.
34.Nyman U, Ringertz NR, Pettersson I: Demonstration of an amino terminal La epitope recognized by human anti-La sera. Immunol Lett 1989;22:65-72.
35.Wahren M, Skarstein K, Blange I, Pettersson I, Jonsson R: MRL/lpr mice produce anti-Ro 52000 MW antibodies: detectin, analysis of specificity and site of production. Immunology 1994;83:9-15.
36.Halse A-K, Wahren-Herlenius M, Jonsson R: Ro/SS-A- and La/SS-B reactive B lymphocytes in peripheral blood of patients with Sjogren’s syndrome. Clin Exp Immunol 1999;115:208-213.
37.Baethge BA, Levine SN, Wolf RE: Antibodies to nuclear antigens in Graves’ disease. J Clin Endocrinol Metab 1988;66:485-488.
38.Katakura M, Yamada T, Aizawa T, et al: Presence of antideoxyribonucleic acid antibody in patients with hyperthyroidism of Graves’ disease. J Clin Endocrinol Metab 1987;64:405-408.
39.Tajiri J, Higashi K, Morita M, et al: Elevation of anti-DNA antidoby titer during thyrotoxic phase of silent thyroiditis. Arch Intern Med 1986;146:1623-1624.
40.Murakami M, Koizumi Y, Aizawa T, et al: Studies of thyroid function and immune parameters in patients with hyperthyroid Graves’ disease in remission. J Clin Endocrinol Metab 1988;66:103-108.
41.McDermott MT, West SG, Emlen JW, et al: Antideoxyribonucleic acid antibodies in Graves’ disease. J Clin Endocrinol Metab 1990;71:509-510.
42.Simmons-O’Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, et al: One hundred anti-Ro(SS-A) antibody positive patients: a 10-year follow-up. Medicine 1995;74:109-130.
43.Provost TT, Talal N, Harley JB, Reichlin M, Alexander E: The relationship between anti-Ro(SS-A) antibody-positive Sjogren’s syndrome and anti-Ro (SS-A) antibody-positive lupus erythematosus. Arch Dermatol 1988;124:63-71.
44.Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P: Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythermatosus. Ann Intern Med 1982;97:664-671.
45.Maddison PJ: Anti-Ro antibodies and neonatal lupus. Clin Rheumatol 1990;9:116-122.
46.Dore N, Synkowski D, Provost TT: Antinuclear antibody determinationsin Ro (SSA)-positive, antinuclear antibody-negative lupus and Sjogren’s syndrome patients. J Am Acad Dermatol 1983;8:611-615.
47.D.F. Mutasim, B.B. Adams: A practical guide for serologic evaluation of autoimmune connective tissue diseases. J Am Acad Dermatol 2000;42:159-174.

第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔